Bio Green Med Solution, Inc.

Regulatory Filings • Apr 21, 2025

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

April 21, 2025

Date of Report (date of earliest event reported)

Cyclacel Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware	0-50626	91-1707622
(State
or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S.
Employer Identification Number)

Level 10, Tower 11 , Avenue 5 , No. 8

Jalan Kerinchi , Kuala Lumpur , Malaysia 592000

(Address of principal executive offices) (Zip code)

(908) 517-7330

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common Stock, par value
$0.001 per share | CYCC | The Nasdaq Capital Market |
| Preferred Stock, $0.001
par value | CYCCP | The Nasdaq Capital Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 8.01 Other Events .

On April 19, 2025, the Board of Directors (the “Board”) of Cyclacel Pharmaceuticals, Inc. (the “Company”) declared a quarterly cash dividend of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock (the “Preferred Stock”). The cash dividend will be payable on May 1, 2025, to Preferred Stock stockholders of record as of the close of business on April 29, 2025.

The Board considered numerous factors in determining whether to declare the quarterly dividend, including the requisite financial analysis and determination of a surplus. While the Board will analyze the advisability of the declaration of dividends in future quarters, there is no assurance that future quarterly dividends will be declared

Field: Page; Sequence: 2; Options: NewSection; Value: 2

2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 21, 2025
By:	/s/
Datuk Dr. Doris Wong Sing Ee
Name:	Datuk Dr. Doris
Wong Sing Ee
Title:	Chief Executive Officer
and Executive Director

Field: Page; Sequence: 3; Options: Last

3

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kd9OgzAUh59g73BCvFxYQWcMd0rmYmSGbMvibQdn2gx6yGmH2yP5lpYieDObJk3b33e+/gmCabCkZ1Uhw/vTOoMt1k0lLcIaD8ioC3SJ9OU1ATeu8UMZy1JbPx3AlByDjrkPxd6t+2SrDJYJiLtZLGbxHMQ8uX2AfBVMuv2U9EGVqK2SFUhdQs7UsEIr+dJX2Mozaaov3rRDNop0AlEo+u1viEUUwxu18ov4aCDL0mAy9W0SLJlOjUstzhZ1R8KiwtrpTE//dX+a4mQs1UnO3Z0Zy42l4ihCIaJc8k5WJ1xhvUd20UjEcSQef08xEuCRKdx4ChrJ0HbcFYt7rZq0zw/VexXy5lPyf6oeGzyjYDS6fzAdPhh/AKj9ivc=